Efavirenz/emtricitabine/tenofovir disoproxil fumarate

Drug Profile

Efavirenz/emtricitabine/tenofovir disoproxil fumarate

Alternative Names: ATR; Atripla

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb; Gilead Sciences; Merck & Co
  • Class Antiretrovirals; Benzoxazines; Nucleotides; Phosphonic acids; Purines
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV infections

Most Recent Events

  • 27 Feb 2017 Gilead Sciences has patent protection for Efavirenz/emtricitabine/tenofovir disoproxil fumarate in USA and European Union (Gilead Sciences 10-K, February 2017)
  • 04 Jun 2008 Atripla® receives reimbursement approval in Quebec from the Quebec Minister of Health
  • 31 Jan 2008 Launched for HIV infections treatment in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top